SBIR and STTR Success Story for
MicroTransponder Inc.

(Information Posted/Updated on 02/24/2011)

MicroTransponder Inc.
2802 Flintrock Trace
Suite 226
Austin, TX  78738

Contact:    Jordan Curnes
Phone:      214-770-0935
Fax:          866-390-4390
E-mail:      jordan@microtransponder.com
Web Site:  http://www.microtransponder.com

Project Title:  SAINT wireless neurostimulation device
Related Award(s):  R44 DC010084-02
Technology Developed:
MicroTransponder is developing the SAINT™ System, a wireless neurostimulation technology platform to treat neurological disease including urinary incontinence, tinnitus, and chronic pain. The SAINT™ is a minimally invasive device that does not require implanted batteries or wires. It is significantly smaller than current neurostimulation devices.

Key Words:  tinnitus, urinary incontinence, neurostimulation, chronic pain, PTSD, Traumatic Brain Injury, medical device, neurosurgery.
Uses of Technology/Products/Service:
The SAINT™ is a small implantable device about the size of 2 grains of rice that can be powered via an external wireless controller to transmit electric pulses to any peripheral nerve in the human body. Once implanted, this electric pulses can help an individual regain normal bladder function, block chronic pain signals, or even create changes in the brain. When placed near a nerve in the neck, it can send signals to the brain to release chemicals or neurotransmitters that allow the brain to rapidly learn new tasks. The initial therapeutic area for the SAINT™ will be treatment for urinary incontinence via stimulation of a nerve in the ankle. However, the dynamic team of neuroscientists and medical device engineers at MicroTransponder is developing the SAINT™ for a pipeline of additional indications based on Vagus Nerve Stimulation, including stroke rehabilitation, tinnitus, and anxiety. MicroTransponder has a substantial neurostimulation focused R&D program which includes an initiative to use the SAINT™ to assist the delivery of chemotherapy treatments for glioblastoma and other cancer therapeutics.

Benefit to Company:
The SBIR program has been essential in allowing MicroTransponder to raise over $10 Million in private funding to develop our medical device. The independent scientific validation and programs like CAP have allowed the company to continue its research in promising areas that may not be as commercially attractive, but that are still very important to those patients suffering with the condition. Tinnitus therapy is a great example. Without support from the NIH, we would have been unable to continue our tinnitus research since existing medical device companies were not willing to take the risk with their capital for such a small and difficult market.

How Product Was Commercialized:
The SAINT™ device is being commercialized via the hard work of an experienced team of medical device engineers and will begin clinical trials in 2012. We are in discussions with several major medical device companies to acquire the device and bring it to market once have demonstrated efficacy in clinical trials. They have large sales teams in the market already.

Other Comments Related to Company's Success Story:
The SBIR program has been a great champion of important research. It has successfully bridged the gap between promising University research and the clinical data that is often needed to secure additional funding.

Past R&D and/or Sales from this Project:   $10M
Estimated Future Annual R&D and/or Sales from this Project:   $20M